Thus, the data from our B16 tumor model and DSS-induced colitis are consistent with clinical observations in patients who received ipilimumab (anti-CTLA-4 antibody), and/or nivolumab (anti-PD-1 antibody), for whom colitis is the most commonly encountered problem. Here, CTLA4 is linked to neoplasm.